Home›Stock Screener›Mankind Pharma›Financial Statements

Mankind Pharma Complete Financial Statements

7 Years of Data
2026 - 2020

In FY2026, Mankind Pharma (MANKIND) reported revenue ₹3,560 Cr, net profit ₹559 Cr and EPS ₹13.44, with a net profit margin of 15.7% and ROE of 3.4%. Full financial statements from FY2020 to FY2026 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore MANKIND investment value to estimate fundamental worth using multiple valuation models.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 15.70% 2026 data
EBITDA Margin 28.76% 2026 data
Operating Margin 26.00% 2026 data
Return on Assets 1.99% 2026 data
Return on Equity 3.43% 2026 data

Balance Sheet Ratios

Current Ratio 1.39 2026 data
Equity Ratio 58.05% 2026 data
Asset Turnover 0.13 2026 data

MANKIND Revenue, Net Profit & EBITDA — Year-on-Year Growth

MANKIND YoY (Mar 2025 vs Mar 2026) — revenue +6.8%, net profit +31.5%, EBITDA +9.8%, expenses +5.6%. For live price, earnings ratios and company overview, see Mankind Pharma screener.

Revenue Growth
+6.8%
Year-over-Year
Net Profit Growth
+31.5%
Year-over-Year
EBITDA Growth
+9.8%
Year-over-Year
Expense Growth
+5.6%
Year-over-Year
Assets Growth
+1.2%
Year-over-Year
Equity Growth
+11.9%
Year-over-Year
Operating Cash Flow Growth
+12.1%
Year-over-Year
Investing Cash Flow Growth
-506.6%
Year-over-Year
Financing Cash Flow Growth
+204560.0%
Year-over-Year

MANKIND Income Statement — Revenue, EBITDA & Net Profit

Mankind Pharma revenue ₹3,560 Cr, EBITDA ₹1,024 Cr, net profit ₹559 Cr, EPS ₹13.44 (2026) — net profit margin 15.7%. Review Mankind Pharma price earnings to evaluate earnings-based valuation against sector peers.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Mar 2023 Jun 2023 Dec 2023 Sept 2022 Mar 2022 Jun 2022 Dec 2022
Revenue 3,560 3,791 3,333 3,653 3,643 3,173 2,517 2,976 3,286 2,772 2,103 2,642 2,682 2,457 1,764 2,200 2,130
Expenses 2,536 2,776 2,401 2,724 2,754 2,217 1,836 2,196 2,383 2,025 1,636 1,924 2,000 1,835 1,441 1,724 1,654
EBITDA 1,024 1,016 933 930 889 956 681 780 903 746 467 718 681 622 323 476 477
Operating Profit Margin % 26.00% 25.00% 22.00% 24.00% 23.00% 28.00% 24.00% 23.00% 26.00% 25.00% 20.00% 25.00% 23.00% 24.00% 17.00% 21.00% 21.00%
Depreciation 223 222 231 219 223 101 100 103 187 97 85 87 110 79 47 78 85
Interest 142 170 191 171 157 7 9 11 221 9 5 6 9 10 13 16 13
Profit Before Tax 659 624 511 541 509 849 572 666 495 641 377 625 562 533 263 382 379
Tax 100 104 86 96 95 190 95 123 111 130 84 130 103 110 70 84 83
Net Profit 559 520 425 445 414 659 477 543 385 511 294 494 460 423 193 298 296
Earnings Per Share (₹) 13.44 12.39 10.19 10.62 9.90 16.31 11.76 13.39 9.46 12.51 7.13 12.15 11.33 10.48 4.74 7.30 7.09

MANKIND Balance Sheet — Assets, Liabilities & Shareholders' Equity

MANKIND total assets ₹28,080 Cr, total equity ₹16,300 Cr, total liabilities ₹ Cr (2026) — ROE 3.4%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021
ASSETS
Total Assets 28,080 27,760 11,963 9,715 9,148 6,373
Current Assets 6,954 6,988 6,568 4,328 4,407 3,907
Fixed Assets 13,256 19,005 4,545 4,251 3,588 1,664
Capital Work in Progress 655 826 282 550 702 372
Investments 2,145 2,042 2,568 1,346 1,110 1,512
Other Assets 0 5,887 4,568 3,568 3,749 2,824
LIABILITIES
Total Liabilities
Current Liabilities 5,011 7,528 268 229 208 156
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 16,300 14,568 9,576 7,623 6,316 4,863
Share Capital 41 41 40 40 40 40
Reserves & Surplus 16,259 14,291 9,323 7,395 6,115 4,682

MANKIND Cash Flow Statement — Operating, Investing & Financing

Mankind Pharma operating cash flow ₹2,413 Cr, investing ₹-12,624 Cr, financing ₹10,233 Cr, net cash flow ₹22 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020
Operating Activities 2,413 2,152 1,813 920 1,137 1,070
Investing Activities -12,624 -2,081 -1,052 -1,369 -1,222 -436
Financing Activities 10,233 5 -740 605 -8 -531
Net Cash Flow 22 77 22 156 -92 103